Fertility Innovation in 2026: AI, IVF Technology and the Companies Competing for Growth

The fertility industry is moving beyond conventional in vitro fertilization (IVF). Artificial intelligence, time-lapse embryo imaging, fertility preservation and personalized treatment planning are creating new opportunities for fertility clinics, medical technology companies and reproductive healthcare investors.

The scale of demand is clear. According to the American Society for Reproductive Medicine (ASRM), 100,158 babies were born through IVF in the United States in 2024, the first time the annual total exceeded 100,000. SART-member clinics reported 449,772 IVF treatment cycles that year.

For businesses, the next phase of competition is about more than increasing treatment volumes. It involves improving laboratory workflows, integrating clinical data, differentiating services and establishing partnerships with fertility clinics.

Download Customized Sample: https://www.towardshealthcare.com/download-sample/5464 

Three Statistics Every Fertility Business Should Know

Sources: ASRM/SART, WHO and the UK Human Fertilisation and Embryology Authority (HFEA).

These figures describe different aspects of fertility care: treatment activity, the underlying health need and the regulated clinic infrastructure. They should not be interpreted as a single measure of commercial demand.

AI in IVF: From Embryo Imaging to Clinical Decision Support

Embryo assessment is one of the most important steps in IVF. Embryologists evaluate embryos using morphological characteristics, developmental timing and other available clinical information to support transfer decisions.

AI tools are entering this workflow by analyzing embryo images and providing additional information to clinicians.

Alife Health: An Emerging AI Company to Watch

Alife Health announced FDA clearance for its Embryo Predict tool on May 28, 2026. The software is intended to provide additional information when embryologists assess Day 5, 6 and 7 blastocysts that have already been considered suitable for transfer or freezing. The company says the tool is supported by a multicenter randomized clinical trial and is commercially available in the United States and Europe.

In July 2026, Alife announced a partnership with First Fertility to deploy Embryo Predict across its clinic network, beginning with the Center for Advanced Reproductive Services. This provides a concrete example of how an emerging fertility technology company can expand through clinic partnerships rather than relying only on direct software sales.

Commercial opportunity: Fertility technology developers can target clinic groups that want to standardize embryo assessment, improve laboratory workflows and integrate AI-supported tools with existing systems.

However, AI scores are not guarantees of implantation or live birth. Clinical validation, appropriate patient populations, transparent performance reporting and regulatory compliance remain important.

Time-Lapse Imaging and Smarter Embryology Laboratories

Time-lapse systems capture embryo development over time while embryos remain inside a controlled incubation environment. This provides embryologists with additional developmental information compared with relying only on scheduled visual assessments.

Its EmbryoScope product family combines embryo incubation with time-lapse imaging. The technology is designed to support embryo observation and assessment while reducing the need to repeatedly remove culture dishes for visual checks.

For clinics, the investment case may include workflow consistency, laboratory capacity and the ability to review embryo development. For technology suppliers, opportunities include imaging systems, incubators, culture dishes, software integration, service contracts and laboratory upgrades.

The commercial question is whether the additional information and workflow benefits justify the equipment, consumable and training costs for a particular clinic.

Fertility Preservation: Building Services Beyond IVF Treatment

Fertility preservation includes egg, sperm and embryo freezing for people who wish to preserve reproductive options. It can be relevant before certain medical treatments, for people delaying parenthood and for individuals whose circumstances may affect future fertility.

The service model requires more than a freezing procedure. It can involve consultations, laboratory equipment, cryostorage, monitoring, consent processes, long-term storage management and future treatment coordination.

Where companies can compete:

• Cryopreservation equipment and storage systems.

• Cryogenic containers, laboratory consumables and sample-tracking software.

• Digital patient management and storage-renewal workflows.

• Clinic partnerships and referral networks.

• Laboratory quality systems and secure data management.

Providers must also consider local regulations, informed consent, storage requirements and the long-term responsibilities associated with stored reproductive material.

Personalized Fertility Treatment and Data Integration

Fertility treatment can involve ovarian stimulation, hormone monitoring, egg retrieval, fertilization, embryo culture and transfer. Treatment planning depends on individual clinical factors, and a single protocol will not be suitable for every patient.

Data-driven platforms can help clinics organize patient information and support decisions about scheduling, medication management and laboratory workflows.

Alife Health's wider platform, for example, includes software designed to support clinic operations and data-informed treatment planning. Its products illustrate a broader direction in fertility technology: connecting laboratory information with the operational and clinical decisions made across a treatment cycle.

Potential opportunities include:

• Electronic medical record integration.

• Automated scheduling and laboratory workflow management.

• Patient communication and treatment coordination.

• Data analysis to identify operational bottlenecks.

• Tools that support individualized clinical review.

Technology vendors should demonstrate how their systems fit existing clinic workflows and protect sensitive reproductive health information. Improved operational efficiency should also be distinguished from proven improvements in pregnancy or live-birth outcomes.

Fertility Clinic Expansion and Partnership Opportunities

The UK provides an example of a regulated clinic network with both private and public-service dimensions. In its 2025/26 report, the HFEA recorded 137 licensed clinics, of which 104 were licensed to provide fertility treatment. Seventy of those treatment clinics were privately owned, and 47 of the private clinics were owned by clinic groups.

For suppliers and technology developers, clinic groups can provide a route to multi-site deployments. For investors and service providers, clinic ownership, location, treatment capabilities and technology adoption can help identify potential partnership opportunities.

Before approaching a clinic or group, companies should assess:

• Number and location of treatment facilities.

• Existing embryology laboratory equipment and software.

• IVF treatment capacity and service mix.

• Current technology partnerships and procurement needs.

• Regulatory requirements and the commercial decision-makers involved.

The number of clinics alone does not establish their purchasing power. More useful intelligence connects clinic ownership and capabilities with actual technology needs and investment plans.

Key Fertility Technology Segments and Commercial Opportunities

These are potential commercial opportunities, not evidence that every technology will improve clinical outcomes or achieve widespread adoption.

What Fertility Companies Should Track in 2026:2027

Fertility businesses need an intelligence system that connects technology developments with real commercial decisions.

Clinical and regulatory intelligence

• FDA clearances, CE marking and other relevant approvals.

• Clinical evidence supporting embryo assessment and treatment tools.

• New indications, validation studies and safety updates.

Competitive intelligence

• Emerging AI developers and established laboratory equipment suppliers.

• New product launches, distribution agreements and clinic partnerships.

• Product positioning, integration capabilities and service models.

Buyer and partnership intelligence

• Fertility clinic groups and independent treatment centres.

• Embryology laboratory decision-makers.

• Equipment distributors, laboratory suppliers and technology integration partners.

• Investors and businesses expanding fertility services.

Geographic intelligence

• Clinic concentration and ownership.

• Country-specific regulations and reimbursement conditions.

• Local procurement needs, affordability constraints and access gaps.

Tracking these factors together can help companies identify where demand exists, which buyers fit their products and what evidence is needed to support adoption.

How Towards Healthcare Supports Fertility Business Growth

Towards Healthcare Research & Consulting supports fertility businesses with strategic intelligence to identify competitors, assess emerging technologies and uncover partnership opportunities.

• Complete Master Datasets: Structured company, clinic, product and technology information.

• Competitive Quadrants: Comparison of fertility technology providers and their capabilities.

• Customized Dashboards: Monitoring of launches, partnerships, clinic networks and strategic developments.

• Buyer Identification: Mapping of potential clinic customers, distributors and technology partners.

• GTM Strategy: Support for geographic expansion, commercial positioning and partnership planning.

Looking for your next fertility technology partner or clinic expansion opportunity? Identify relevant companies, track emerging innovations and uncover strategic opportunities with Towards Healthcare.

About Us

Healthcare Web Wire is a part of Towards Healthcare, which is a healthcare intelligence and market research company specializing in market intelligence, competitive intelligence, customer intelligence, pipeline intelligence, market sizing and commercial strategy across pharmaceutical, biotechnology, medical device and healthcare markets.

Contact us for quick meeting, customized data, free samples or further enquiry at [email protected]

Europe Region - +44 778 256 0738

North America Region - +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com

Find us on social platforms: LinkedIn | Twitter | Instagram